- Home
- CE vs VKTX Comparison
CE vs VKTX Comparison
Compare CE & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CE | VKTX |
|---|---|---|
| Founded | 1918 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.8B |
| IPO Year | 2005 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CE | VKTX |
|---|---|---|
| Price | $48.04 | $33.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 14 |
| Target Price | $55.82 | ★ $87.07 |
| AVG Volume (30 Days) | 1.8M | ★ 3.3M |
| Earning Date | 02-17-2026 | 02-05-2026 |
| Dividend Yield | ★ 0.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,710,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.13 | $18.92 |
| 52 Week High | $75.84 | $43.15 |
Technical Indicators
Market Signals| Indicator | CE | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.34 | 47.00 |
| Support Level | $43.73 | $31.71 |
| Resistance Level | $47.89 | $36.00 |
| Average True Range (ATR) | 2.13 | 2.01 |
| MACD | 0.21 | 0.09 |
| Stochastic Oscillator | 94.79 | 55.04 |
Price Performance
Historical ComparisonAbout CE Celanese Corporation
Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.